Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$111.35 USD

111.35
891,782

+0.05 (0.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $111.30 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

by Zacks Equity Research

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

Zacks Equity Research

Stock Market News for Nov 22, 2021

by Zacks Equity Research

Wall Street closed mixed on Friday to end a choppy week.

Zacks Equity Research

FDA Gives Authorization to Two COVID-19 Boosters

by Zacks Equity Research

FDA Gives Authorization to Two COVID-19 Boosters

Mark Vickery headshot

FDA Authorizes Covid Boosters; New Fed Chair Soon?

by Mark Vickery

Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."

Kinjel Shah headshot

3 Big Pharma Outperformers to Watch Out For in the Near Term

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Daniel Laboe headshot

The Stock Market Rally Is Back In High Gear

by Daniel Laboe

All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?

Zacks Equity Research

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research

On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Zacks Equity Research

Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research

BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.

Zacks Equity Research

Better-Than-Expected Private Payrolls in October

by Zacks Equity Research

Better-Than-Expected Private Payrolls in October.

Mark Vickery headshot

ADP: 571K New Private-Sector Jobs, Better than Expected

by Mark Vickery

571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.

Nalak Das headshot

5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone

by Nalak Das

We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings

by Zacks Equity Research

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.

Zacks Equity Research

Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up

by Zacks Equity Research

Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $274.32, moving -1.58% from the previous trading session.

Zacks Equity Research

How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Zacks Equity Research

Stock Market News for Nov 1, 2021

by Zacks Equity Research

Wall Street closed higher on Friday despite weak earnings results of a couple of technology behemoths.

Nalak Das headshot

Top 6 Momentum Picks for November After a Fabulous October

by Nalak Das

We have narrowed down our search to six large-cap momentum stocks that have strong upside left for the rest of 2021. These are: BX, Ce, CLR, XLNX, BG, GPC.

Zacks Equity Research

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) closed at $292.39 in the latest trading session, marking a -0.86% move from the prior day.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Gain on Positive COVID-19 Booster Dose Data?

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in the coronavirus vaccine.

Mark Vickery headshot

Big Week for FAANG, Economic Reads

by Mark Vickery

The Dow is +25 points, the S&P 500 +5 and the tech-heavy Nasdaq, which houses the FAANG stocks, is +45 points at this hour.

Zacks Equity Research

Tech Giants to Report Earnings This Week

by Zacks Equity Research

Tech Giants to Report Earnings This Week

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT